| Aug 13 |
Jaguar Health GAAP EPS of -$4.04 misses by $2.84, revenue of $2.72M misses by $0.71M
|
| Aug 13 |
Jaguar Health Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
Jaguar Health Q2 2024 Earnings Preview
|
| Aug 12 |
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
|
| Aug 5 |
Jaguar Health to Detail Regulatory Strategy for Antidiarrheal Drug for Cancer Patients Next Week
|
| Aug 2 |
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
|
| Aug 1 |
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
|
| Jul 31 |
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
|
| Jul 23 |
Jaguar stock plunges 60% on failed Phase 3 study for crofelemer
|
| Jul 23 |
Jaguar Health, Inc. (JAGX) Special Call Transcript
|
